Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).

Abstract

There is accumulating evidence that advanced glycation end products (AGEs) play a role in the development and progression of chronic kidney disease (CKD). We have previously found that atorvastatin treatment significantly reduces serum levels of AGEs in type 2 diabetic patients and subjects with non-alcoholic steatohepatitis in a cholesterol lowering-independent manner. In this study, we examined whether atorvastatin could reduce proteinuria partly via reduction of serum levels of AGEs in non-diabetic CKD patients. Ten non-diabetic normotensive stage I or II CKD patients with dyslipidemia were enrolled. Patients were treated with atorvastatin (10 mg/day) for 1 year. All subjects underwent determination of blood chemistries, proteinuria and serum levels of AGEs at baseline and after 1 year. Atorvastatin treatment for 1 year significantly decreased circulating levels of total cholesterol, LDL-cholesterol, triglycerides, and AGEs, while it increased HDL-cholesterol levels. Further, although atorvastatin treatment did not affect estimated glomerular filtration rate, it significantly reduced proteinuria. In univariate analyses, proteinuria levels were correlated with total cholesterol, LDL-cholesterol, triglycerides, HDL-cholesterol (inversely) and AGEs. Multiple stepwise regression analysis revealed that AGE level was a sole independent correlate of proteinuria. In this initial examination of the patients in this study, our present study suggests that atorvastatin could decrease proteinuria in non-diabetic CKD patients with dyslipidemia partly via reduction of serum levels of AGEs. Atorvastatin may have AGE-lowering effects in CKD patients as well that could contribute to renoprotective properties of this agent.

• Authors: Tsukasa Nakamura, Eiichi Sato, Nobuharu Fujiwara, Yasuhiro Kawagoe, Masayoshi Takeuchi, Sayaka Maeda, Sho-ichi Yamagishi
• Journal: Oxidative medicine and cellular longevity (Oxid Med Cell Longev) 2010 Sep-Oct Vol. 3 Issue 5 Pg. 304-7 ISSN: 1942-0994 [Electronic] United States
• PMID: 21150335 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anticholesteremic Agents
• Cholesterol, HDL
• Cholesterol, LDL
• Glycation End Products, Advanced
• Heptanoic Acids
• Pyrroles
• Triglycerides
• Cholesterol
• Atorvastatin

Topics

• Adult
• Anticholesteremic Agents (therapeutic use)
• Atorvastatin
• Cholesterol (blood)
• Cholesterol, HDL (blood)
• Cholesterol, LDL (blood)
• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Female
• Glycation End Products, Advanced (blood)
• Heptanoic Acids (therapeutic use)
• Humans
• Kidney Failure, Chronic (complications, drug therapy, metabolism)
• Male
• Proteinuria (drug therapy)
• Pyrroles (therapeutic use)
• Severity of Illness Index
• Triglycerides (blood)